Attorney General Alan Wilson has announced a substantial $7.4 billion settlement with Purdue Pharma and the Sackler family, a significant step towards addressing the devastating impact of the opioid crisis in South Carolina. This agreement comes from a bipartisan coalition of attorneys general who pushed for accountability from Purdue Pharma for its role in fueling the epidemic.
Wilson emphasized the importance of this settlement, stating, “South Carolina will stop at nothing to protect its citizens and deliver justice to those who have been harmed.” He has been a longstanding advocate for holding Purdue and the Sackler family accountable, asserting that their actions have led to immense suffering and loss for countless families.
The settlement not only entails the hefty financial payment but also secures the permanent removal of the Sackler family from any control over Purdue Pharma. Furthermore, they will be prohibited from selling opioids in the United States, marking a critical move towards preventing future harm.
Related Recipes
SpaceX targets June 12 Nasdaq debut under SPCX with sizable retail allocation, valuation up to $2 trillion
Clermont Memorial Day Ceremony Honors Veterans, Recognizes Tuskegee Airman Daniel Keel
Christy Lane Fire Triggers Evacuations in Iron County, Utah as Crews Battle Blaze
American Airlines Faces Record Cancellations at DFW as Memorial Day Storms Roil Travel
As part of the settlement, South Carolina is set to receive around $72.8 million over the next 15 years. This funding aims to bolster efforts in opioid addiction treatment, prevention, and recovery initiatives, offering hope to individuals and families affected by addiction.
Trending Now
FA appoints Thomas Tuchel as England head coach for 2026 World Cup bid
AEP expands five-year plan to power data centers with $4.2 billion Piketon transmission project after FERC OVEC restructuring approval
Good Housekeeping Names Sleep Number True Temp Blanket Best Cooling Blanket After Testing 68 Blankets With 200 Sleepers
UC Academic Senate launches yearlong review of undergraduate admissions, weighing SAT/ACT reinstatement and A‑G course reassessment
This landmark decision serves as a powerful reminder of the potential for justice in the face of corporate negligence and the necessity of collective action among states to combat the opioid crisis. It reflects a growing movement to hold pharmaceutical companies accountable for their role in public health crises.
Continue Reading
